Login to Your Account

Arakis, Vectura Enter Potential $375M Novartis Deal For AD 237

By Nuala Moran

Wednesday, April 20, 2005
LONDON - Two UK companies with a jointly developed product signed one of the biggest deals to date in European biotechnology, agreeing to a potential $375 million license with Novartis AG for their treatment of chronic obstructive pulmonary disease (COPD). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription